Abstract #2395
The measurement of the characteristics of the metabolic syndrome and the effect of a targeted treatment of rosiglitazone
Ernst Suidgeest 1 , Bigit Den Adel 1,2 , Jos W.A. Van der Hoorn 3 , Rob E Poelmann 4 , and Louise Van der Weerd 1,5
1
Radiology, LUMC, Leiden, Netherlands,
2
Anatomy,
LUMC, Netherlands,
3
Metabolic
Health Research, TNO, Leiden, Netherlands,
4
Anatomy,
LUMC, Leiden, Netherlands,
5
Human Genetics,
LUMC, Netherlands
The objectives of this study were: 1. to establish
whether rosiglitazone administration causes cardiac
dysfunction in a mouse model. 2. to establish whether
liposome-encapsulation reduces these side effects, if
present, and 3. to investigate whether liposomal
delivery of rosiglitazone preserves the therapeutic
response compared to standard rosiglitazone. This study
shows that MRI is a tool that can be used to assess the
diverse aspects of metabolic syndrome. We showed that
rosiglitazone at a standard clinical dose induces
dilated cardiomyopathy and weight gain in the LDLr-/-
mouse model. Micelle encapsulation of rosiglitazone
significantly improves these unwanted side effects.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
